dabigatran has been researched along with Acute Disease in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.50) | 29.6817 |
| 2010's | 33 (82.50) | 24.3611 |
| 2020's | 6 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bloom, B; Cohen-Aubart, F; Freund, Y | 1 |
| Antoniolli, M; Barrionuevo, B; Bernal, MI; Cigalini, IM; Lerech, E; Morcos, L; Scatularo, CE; Zaidel, EJ | 1 |
| Darius, H | 1 |
| Ahn, SH; Cho, HJ; Choi, HY; Choi, JK; Han, SW; Heo, JH; Jung, YH; Kang, YJ; Kim, WJ; Kim, YD; Kwon, JH; Lee, KY; Nam, HS; Park, HJ; Park, JH; Seo, JH; Sung, SM | 1 |
| Hofmann, ER; Isaacs, DJ; Johnson, EJ; Rangarajan, S; Vinson, DR | 1 |
| Albisetti, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gorbatikov, K; Gropper, S; Halton, J; Huang, F; Kreuzer, J; Luciani, M; Mitchell, LG; Nurmeev, I; Reilly, P; Sharathkumar, A; Simetzberger, M; Sun, Z; Svirin, P; Tartakovsky, I | 1 |
| Langer, F; Voigtlaender, M | 1 |
| Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schüler, E; Schulman, S | 1 |
| Ageno, W; Barco, S; Binder, H; Brenner, B; Duerschmied, D; Empen, K; Faggiano, P; Ficker, JH; Galiè, N; Ghuysen, A; Held, M; Heydenreich, N; Huisman, MV; Jiménez, D; Klok, FA; Konstantinides, SV; Kozak, M; Lang, IM; Lankeit, M; Meyer, G; Münzel, T; Petris, A; Pruszczyk, P; Quitzau, K; Schellong, S; Schmidt, KH; Stefanovic, BS; Verschuren, F; Wolf-Puetz, A | 1 |
| Abdul-Rahim, AH; Acampa, M; Acciarresi, M; Ageno, W; Agnelli, G; Alberti, A; Athanasakis, G; Bandini, F; Becattini, C; Bellesini, M; Bono, G; Bovi, P; Cappellari, M; Carletti, M; Carolei, A; Caso, V; Chiti, A; Chondrogianni, M; Ciccone, A; Cimini, LA; Colombo, G; Consoli, D; Corea, F; D'Amore, C; De Lodovici, ML; Denti, L; Falocci, N; Flomin, Y; Furie, KL; Galati, F; Gialdini, G; Giannini, N; Giorli, E; Giuntini, M; Gourbali, V; Guideri, F; Karagkiozi, E; Karapanayiotides, T; Kargiotis, O; Lanari, A; Lees, KR; Letteri, F; Liantinioti, C; Lorenzini, G; Lotti, EM; Maccarrone, M; Maimone Baronello, M; Makaritsis, K; Mancuso, M; Marcheselli, S; Martini, G; Masotti, L; Monaco, S; Mosconi, MG; Mumoli, N; Ntaios, G; Orlandi, G; Paciaroni, M; Padovani, A; Pezzini, A; Poli, L; Putaala, J; Sacco, S; Scoditti, U; Silvestrelli, G; Sohn, SI; Soloperto, R; Tadi, P; Tassi, R; Tassinari, T; Tatlisumak, T; Tiseo, C; Tomppo, L; Toni, D; Tsivgoulis, G; Vadikolias, K; Vannucchi, V; Venti, M; Yaghi, S; Zedde, M | 1 |
| Caruso, K; Kanter, M | 1 |
| Barcellona, D; Cianchetti, ME; Mameli, A; Marongiu, F; Musu, M; Porru, M; Ruberto, F | 1 |
| Carey, R; Nelatur, V | 1 |
| Antunovic, M; Dzudovic, B; Dzudovic, J; Obradovic, S; Stavric, M; Subota, V; Subotic, B | 1 |
| Arbel, M; Ayata, C; Bacskai, BJ; Böhm, M; Boulouis, G; Endres, M; Fischer, P; Frosch, MP; Greenberg, SM; Qin, T; Schlunk, F; Tamim, I | 1 |
| Hallows, KR; Henry, BL; Maw, TT; Nolin, TD; Pastor-Soler, NM; Singh, T; Unruh, ML | 1 |
| Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N | 1 |
| Ansell, J; Mantha, S | 1 |
| Greig, SL; McKeage, K | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 2 |
| Bamps, S; Decramer, T; Theys, T; Thijs, V; Van Loon, J; Vandenbussche, N; Verhamme, P | 1 |
| Amato, A; Dentali, F; Dumonceau, JM; Paggi, S; Radaelli, F; Repici, A; Rondonotti, E | 1 |
| Hendrickson, JE; Rinder, HM; Siddon, AJ; Tormey, CA | 1 |
| Jugrin, AV; Lamotte, M; Sunderland, T; Urbich, M; Ustyugova, A | 1 |
| Condliffe, R; Elliot, CA; Hurdman, J; Kiely, DG; Maclean, RM; Quadery, R; Sabroe, I; van Veen, JJ | 1 |
| Gonzalez, MG; Levy, PD; Peacock, WF; Than, M | 1 |
| Boda, Z | 1 |
| Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schueler, E; Schulman, S | 1 |
| Ageno, W; Casella, IB; Desch, M; Goldhaber, SZ; Han, CK; Kimura, K; Raskob, GE; Schellong, S; Schulman, S; Singer, DE; Tang, W | 1 |
| Barcellona, D; Cianchetti, ME; Mameli, A; Marongiu, F; Musu, M; Porru, M; Ruberto, MF; Schirru, P | 1 |
| Blanc, Q; Duntze, J; Hanf, W; Hida, H; Reynaud, C | 1 |
| Chiu, L; Chong, CA | 1 |
| Dempfle, CE; Hennerici, MG | 1 |
| Mandel, RJ; Sibley, PA | 1 |
| Huff, CM; Nguyen, TM; Phelan, MP; Rychwalski, PJ; Werdich, XQ | 1 |
| Crowther, MA; Siegal, DM | 1 |
11 review(s) available for dabigatran and Acute Disease
| Article | Year |
|---|---|
Acute Pulmonary Embolism: A Review.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dabigatran; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Pulmonary Embolism; Risk; Rivaroxaban; United States; Vitamin K; Warfarin | 2022 |
Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Topics: Acute Disease; Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasms; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2017 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thrombosis | 2015 |
Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence.
Topics: Acute Disease; Administration, Oral; Benzimidazoles; Dabigatran; Humans; Pyridines; Recurrence; Venous Thromboembolism | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Management of anticoagulation in patients with acute gastrointestinal bleeding.
Topics: Acenocoumarol; Acute Disease; Algorithms; Anticoagulants; Coagulants; Dabigatran; Endoscopy, Gastrointestinal; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Vitamin K; Warfarin | 2015 |
Target-specific Oral Anticoagulants in the Emergency Department.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
[Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Severity of Illness Index; Surgical Procedures, Operative; Thiazoles | 2016 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Plasma; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Dialysis; Renal Insufficiency; Risk Factors; Rivaroxaban; Thiophenes | 2013 |
4 trial(s) available for dabigatran and Acute Disease
| Article | Year |
|---|---|
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Anticoagulants; Child; Child, Preschool; Dabigatran; Disease-Free Survival; Female; Humans; Infant; Male; Survival Rate; Venous Thromboembolism | 2021 |
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
Topics: Acute Disease; Anticoagulants; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Hemorrhage; Heparin; Humans; Male; Prospective Studies; Pulmonary Embolism; Recurrence; Reference Standards; Research Design; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Differences between activities of coagulation factors after one month of therapy with different direct oral anticoagulant in pulmonary embolism patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Blood Coagulation Factors; Dabigatran; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thrombin; Treatment Outcome | 2019 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Risk Factors; Venous Thromboembolism; Warfarin; Young Adult | 2014 |
25 other study(ies) available for dabigatran and Acute Disease
| Article | Year |
|---|---|
Predictors of use of direct oral anticoagulants in acute pulmonary embolism.
Topics: Acute Disease; Anticoagulants; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Pulmonary Embolism; Rivaroxaban | 2022 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality Therapy; Cyclophosphamide; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stents; Stroke; Vitamin K | 2020 |
Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests.
Topics: Acute Disease; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Brain Ischemia; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Partial Thromboplastin Time; Prognosis; Prothrombin Time; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Stroke | 2020 |
Primary care physicians comprehensively manage acute pulmonary embolism without higher-level-of-care transfer: A report of two cases.
Topics: Acute Disease; Adult; Ambulatory Care; Anticoagulants; Antithrombins; Chest Pain; Computed Tomography Angiography; Dabigatran; Decision Making, Shared; Dyspnea; Enoxaparin; Hospitalization; Humans; Male; Middle Aged; Myelitis, Transverse; Patient Transfer; Physicians, Primary Care; Pulmonary Embolism; Risk Assessment; Treatment Outcome; Venous Thrombosis | 2020 |
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
Topics: Acute Disease; Adult; Age Factors; Aged; Aging; Anticoagulants; Antithrombins; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Survival Rate; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Re: Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.
Topics: Acute Disease; Antithrombins; Dabigatran; Drug Overdose; Hepatitis; Humans | 2018 |
Re. Re. Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment and review of the literature.
Topics: Acute Disease; Antithrombins; Dabigatran; Drug Overdose; Hepatitis; Humans | 2018 |
Spontaneous splenic rupture secondary to dabigatran: the last in a series of unfortunate events.
Topics: Accidental Falls; Acute Disease; Aged; Ankle Fractures; Anticoagulants; Dabigatran; Female; Head; Humans; Magnetic Resonance Imaging; Pulmonary Edema; Radiography, Abdominal; Splenic Rupture; Takotsubo Cardiomyopathy; Troponin | 2018 |
Secondary Bleeding During Acute Experimental Intracerebral Hemorrhage.
Topics: Acute Disease; Animals; Anticoagulants; Cerebral Hemorrhage; Dabigatran; Hemorrhage; Male; Mice; Random Allocation; Warfarin | 2019 |
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
Topics: Accidental Falls; Acute Disease; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Colonic Diseases; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Intestinal Perforation; Intestinal Volvulus; Leg Ulcer; Male; Renal Dialysis; Subarachnoid Hemorrhage | 2013 |
New oral anticoagulants for acute venous thromboembolism.
Topics: Acute Disease; Anticoagulants; Benzimidazoles; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism | 2014 |
Dabigatran-associated spontaneous acute cervical epidural hematoma.
Topics: Acute Disease; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cervical Vertebrae; Dabigatran; Hematoma, Epidural, Spinal; Humans; Male; Prothrombin | 2015 |
Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?
Topics: Acute Disease; Aged; Benzimidazoles; beta-Alanine; Dabigatran; Decision Making; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Thrombin Time | 2015 |
The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Topics: Acute Disease; Anticoagulants; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Drug Costs; Hemorrhage; Humans; Kaplan-Meier Estimate; Models, Economic; Pulmonary Embolism; Quality-Adjusted Life Years; State Medicine; Time Factors; Treatment Outcome; United Kingdom; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2015 |
Management of acute pulmonary embolism.
Topics: Acute Disease; Age Factors; Ambulatory Care; Anticoagulants; Antithrombins; Comorbidity; Dabigatran; Disease Management; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Male; Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Cardiovascular; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thrombolytic Therapy; Tissue Plasminogen Activator; Vena Cava Filters; Warfarin | 2015 |
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Thrombophilia; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2016 |
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
Topics: Acute Disease; Anticoagulants; Antithrombins; Blood Coagulation; Cross-Sectional Studies; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pulmonary Embolism; Research Design; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2017 |
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.
Topics: Acute Disease; Aged; Atrial Fibrillation; Coma; Dabigatran; Drug Overdose; Heart Failure; Hemodiafiltration; Hepatitis; Humans; Male; Renal Insufficiency, Chronic; Stroke | 2017 |
[The implication of a direct antithrombine in the appearance of (serious) postoperative acute respiratory distress].
Topics: Acute Disease; Aged; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Humans; Male; Postoperative Complications; Pyridines; Respiratory Distress Syndrome; Severity of Illness Index | 2009 |
Dabigatran and acute stroke thrombolysis.
Topics: Acute Disease; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Contraindications; Dabigatran; Drug Administration Schedule; Female; Humans; Infarction, Middle Cerebral Artery; Pyridines; Thrombolytic Therapy | 2010 |
Dabigatran and stroke thrombolysis.
Topics: Acute Disease; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Contraindications; Dabigatran; Drug Administration Schedule; Drug Monitoring; Humans; Pyridines; Risk Assessment; Stroke; Thrombolytic Therapy | 2010 |
Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran.
Topics: Acute Disease; Antithrombins; Benzimidazoles; beta-Alanine; Carpal Tunnel Syndrome; Dabigatran; Decompression, Surgical; Hematoma; Humans; Male; Middle Aged | 2012 |
Subconjunctival hemorrhage in a patient on dabigatran (Pradaxa).
Topics: Acute Disease; Aged; Antithrombins; Benzimidazoles; Conjunctival Diseases; Dabigatran; Eye Hemorrhage; Humans; Male; Pyridines | 2013 |